Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com

Jefferies reiterated a Buy rating on Praxis Precision Medicines and a $525 price target, implying meaningful upside from the current $339.90 share price. The FDA accepted the NDA for ulixacaltamide in essential tremor and set a PDUFA date of Jan. 29, 2027, with Jefferies assigning a 75% to 80% approval probability. Praxis is targeting more than $10 billion in U.S. peak sales, while Jefferies estimates $3 billion to $3.5 billion.

Analysis

PRAX is now in the awkward middle of a binary de-risking phase: the core event is no longer “does the story exist?” but “how much approval probability is already embedded in the equity?” When a pre-launch asset gets rerated this far ahead of PDUFA, the marginal buyer becomes long-duration capital chasing regulatory optionality, which tends to inflate volatility into any data presentation or FDA communication. The market is likely underpricing how much of the next leg comes from label breadth, dosing convenience, and physician adoption curves rather than from the approval event itself.

The second-order winner is not just PRAX, but any capital-light neurology platform with adjacent readouts, because success here validates premium pricing for rare/underserved movement disorders and encourages investors to fund follow-on pipelines at richer multiples. The loser set is more subtle: mid-cap biopharmas without a near-term regulatory catalyst may see relative multiple compression as funds rotate into names with clearer binary upside, especially if this asset continues to trade as a quasi-approved story. If the company’s own sales assumptions remain aggressive versus external peak-sales math, the stock can still gap higher on approval but fail to hold gains if the commercial path looks narrower than the current narrative implies.

Near term, the key risk is not rejection alone; it is any sign of longer review friction, CMC questions, or label limitations that reduce addressable adoption. Over months, the bigger risk is valuation compression if the market starts discounting a long wait to 2027 as dead capital rather than active upside. Conversely, if management can keep investors focused on real-world physician adoption and payer logic, the stock can continue to behave like a scarcity asset despite being expensive on traditional biotech metrics.

Key Decisions for Investors

• Stay long PRAX, but reduce sizing into strength and treat it as a volatility trade rather than a core fundamental hold; risk/reward is favorable only if you can tolerate a 20-30% drawdown on any regulatory hiccup before the next catalyst.
• Buy PRAX Jan-2027 call spreads or long-dated call diagonals instead of common stock to express approval upside while capping valuation compression risk; best entry is on post-event pullbacks or after low-volume consolidation.
• Pair trade: long PRAX / short a basket of late-stage biopharma names without regulatory catalysts over the next 1-3 months; the trade benefits from capital rotation toward binary names if biotech risk appetite remains selective.
• If already long, hedge event risk with short-dated puts around major presentation dates or FDA interaction windows; the premium should be manageable relative to the 15-20% gap risk from any label/CMC surprise.
• For catalyst traders, take profits into any pre-PDUFA rally and reload only on material pullbacks; the setup has more upside optionality than immediate fundamental certainty, so timing matters more than conviction.